Director Dennis G. Podlesak filed a Form 144 notice with the SEC on October 29, 2026, disclosing a proposed sale of 8,000 shares of Syndax Pharmaceuticals, Inc. common stock under Rule 144 of the Securities Act of 1933.

Key Highlights

  • Filer: Dennis G. Podlesak, a director of Syndax Pharmaceuticals, Inc.
  • Shares proposed for sale: 8,000 shares of common stock, with an aggregate market value of $114,560.00.
  • Shares outstanding: 89,297,086 shares of common stock as reported in the filing.
  • Acquisition method: Shares were acquired on October 29, 2026, through the exercise of stock options from the issuer, with payment made in cash.
  • Broker: Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.
  • Trading plan: The filing indicates reliance on Rule 10b5-1, with a plan adoption date of December 15, 2025.
  • Prior sales: The filing reports nothing to disclose for securities sold in the past three months.

Podlesak's Proposed Stock Sale Details at Syndax Pharmaceuticals

According to the Form 144 filing, Dennis G. Podlesak, identified as a director of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX), proposed to sell 8,000 shares of the company's common stock with an approximate sale date of October 29, 2026. The aggregate market value of the shares to be sold is listed as $114,560.00. The filing was submitted to the SEC on October 29, 2026, with Morgan Stanley Smith Barney LLC Executive Financial Services named as the broker for the transaction.

The filing discloses that the 8,000 shares were acquired on October 29, 2026, through the exercise of stock options, with the issuer listed as the person from whom the securities were acquired, and cash as the nature of payment. The total shares outstanding of Syndax Pharmaceuticals common stock are reported as 89,297,086 at the time of the notice.

The notice indicates that Podlesak is relying on Rule 10b5-1 under the Exchange Act, with the plan adoption date listed as December 15, 2025. By signing the form and indicating that date, the filer represents that the required conditions were met as of the plan adoption date. The filing further states that no securities of the issuer were sold by Podlesak during the past three months.

What Was Disclosed

Syndax Pharmaceuticals director Dennis G. Podlesak filed a Form 144 notice proposing to sell 8,000 shares of common stock acquired through stock option exercise, with an aggregate market value of $114,560.00, under a Rule 10b5-1 plan adopted December 15, 2025.